March 26, 2020 / 11:21 AM / 7 days ago

BRIEF-Prevail Therapeutics Reports Full Year 2019 Financial Results And Business Highlights

March 26 (Reuters) - Prevail Therapeutics Inc:

* PREVAIL THERAPEUTICS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

* PREVAIL THERAPEUTICS INC - DOSING INITIATED IN PROPEL PHASE 1/2 TRIAL OF PR001 FOR TREATMENT OF PARKINSON’S DISEASE WITH GBA1 MUTATIONS

* PREVAIL THERAPEUTICS INC - EXPECTS ITS CURRENT CASH POSITION TO BE SUFFICIENT TO FUND OPERATING EXPENSES INTO FIRST HALF OF 2022

* PREVAIL THERAPEUTICS INC - INITIATION OF PROCLAIM PHASE 1/2 TRIAL PLANNED FOR MID-2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below